timothy sykes logo
MOS Surges As Mosaic Debt Tender And Bioscience Launch Lift Outlook Thumbnail
G Google News

MOS Surges As Mosaic Debt Tender And Bioscience Launch Lift Outlook

JACK KELLOGG•UPDATED AUG. 21, 2026, 4:08 PM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Mosaic Company (The) stocks have been trading up by 6.0 percent amid bullish sentiment on stronger fertilizer demand and pricing power.

What Traders Need To Know

  • RBC kept an Outperform on Mosaic Company (The) with a $27 target, pointing to a slow phosphate margin recovery and better free cash flow from lower capex and a large H2 working-capital reversal.
  • BNP Paribas raised its MOS price target to $32 from $27, kept an Outperform, and the overall analyst stance sits overweight with a mean target around $27.
  • Q2 2026 adjusted EPS came in at $0.13 versus $0.12 expected, a small beat that shows Mosaic Company (The) managing a weak pricing tape slightly better than feared.
  • Management launched and then completed up to $1.4B of note tenders due 2027–2029, funded by new senior notes, cutting gross debt and pushing out near- to medium-term maturities.
  • Through Mosaic Biosciences, the group rolled out Renuvis Enzara, an enzyme-based residue product that targets faster crop breakdown and better field conditions for growers.

Candlestick Chart

Weekly Update Aug 17 – Aug 21, 2026: On Friday, August 21, 2026 Mosaic Company (The) stock [NYSE: MOS] is trending up by 6.0%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Materials industry expert:

Analyst sentiment – positive

Mosaic’s current positioning reflects cyclical trough economics but a solid asset base. Revenue of ~$12.1B is down 10% over three years, with gross margin at 11% and EBIT margin depressed, yielding a negative 5% net margin and LTM ROE of roughly -5%. Nonetheless, a 0.6x P/B and 0.6x EV/sales imply deep value versus global fertilizer peers. Balance sheet leverage is moderate (D/E 0.54, interest cover 6.3x), with tight liquidity (quick ratio 0.1) but adequate working capital.

Technically, the stock has broken sharply higher on the weekly tape, moving from ~21.2 to 24.6 in five sessions, creating a clear short-term uptrend with expanding daily ranges that typically coincide with rising volume. The 22.00–22.30 region now represents key breakout support. For active traders, the actionable level is a pullback buy zone around 23.00–23.20, with a protective stop below 22.20 and upside targeting the 26.50–27.00 area over the coming weeks.

Fundamental and technical catalysts align positively versus the broader Materials and Ag inputs complex. Street targets cluster around $27, with multiple Outperform ratings and upward revisions as investors price in phosphate margin recovery, sulfur-driven tightening, and FCF improvement from lower capex and working-capital release. Debt-tender activity de-risks the curve, while Mosaic Biosciences’ Renuvis Enzara adds optionality in higher-value solutions. I set a 12–18 month target of $28, with support at $22 and resistance near $27–28.

More Breaking News

Quick Financial Overview

MOS is trading around the mid-$20s after a steady climb from roughly $21 to $24–$25 over the recent weekly bars, showing a clean short-term uptrend. The most recent weekly candle pushed to about $24.60, breaking the prior $23–$24 band and signaling buyers are willing to pay up as sentiment turns. Intraday, the 5-minute chart shows tight action between $24.40 and $24.70 for most of the afternoon before a close near $24.60, which tells you supply is getting absorbed rather than rejected.

Under the hood, Mosaic Company (The) is a low-multiple, asset-heavy name. With about $12.05B in annual revenue and a price-to-sales ratio near 0.58, the market is not paying a growth premium. Gross margin sits around 11%, while EBIT margin is just 0.4%, reflecting the current trough part of the fertilizer cycle. Profitability metrics are mixed, with negative recent profit margins and return on equity last twelve months slightly below zero, but long-term ROE and ROIC still positive, hinting at cyclical pressure rather than a broken model.

Balance sheet strength is a key piece of the MOS trade. Total debt-to-equity of 0.54, interest coverage of 6.3, and a current ratio of 1.3 show a levered but manageable structure. The $1.4B tender offers for notes due 2027–2029, followed by completion and slight upsizing of the 2029 tranche, directly support that view by reducing near-term maturities. At the same time, free cash flow for the latest quarter was negative at about -$152.9M, driven by heavy capex and a working-cap build, so the stock still trades like a cyclical recovery story rather than a clean cash machine.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”